Farmaci antiasmatici: stabilizzatori dei mastociti e farmaci anti-IgE

Mast cell stabilizers like cromolyn and nedocromil work by blocking mast cell activation, which prevents histamine release into airways. Unlike other treatments, they do not affect smooth muscle tone. These drugs effectively reduce nasal congestion, coughing, wheezing, and breathlessness when administered via inhalation.

Mast cell stabilizers have weak anti-inflammatory effects and short duration of action, limiting their clinical use. While they effectively alleviate symptoms, their modest impact on underlying inflammation makes them less suitable as monotherapy. Side effects include throat irritation, cough, wheezing, and unpleasant taste sensations at deposition sites.

Omalizumab is a monoclonal antibody that targets IgE antibodies and prevents their binding to mast cells. By inhibiting IgE-mast cell interaction, it prevents mast cell degranulation and blocks the allergic inflammatory cascade. Administered subcutaneously, omalizumab effectively lowers plasma IgE levels and reduces asthma severity and exacerbation frequency.

Mast cell stabilizers such as cromolyn and nedocromil are administered via inhalation, allowing direct delivery to airways. In contrast, omalizumab, an anti-IgE monoclonal antibody, is administered subcutaneously to achieve systemic effects and lower plasma IgE levels effectively throughout the body.

Omalizumab is generally well tolerated, with mild adverse effects including injection-site reactions and viral or upper respiratory tract infections. However, potential anaphylactic reactions are possible and require careful monitoring. These side effects are generally manageable compared to the benefits of reduced asthma severity and exacerbation frequency.

Mast cell stabilizers prevent histamine release by blocking mast cell activation without affecting smooth muscle tone, distinguishing them from bronchodilators. They are administered by inhalation and provide symptom relief but lack strong anti-inflammatory action. Other antiasthma drugs like inhaled corticosteroids and glucocorticoids offer more potent inflammation control.

Omalizumab provides a targeted approach by directly inhibiting IgE-mediated allergic responses, controlling asthma severity and reducing exacerbation frequency. It is particularly valuable for patients with IgE-driven asthma who may not respond adequately to conventional therapies. Despite potential anaphylactic risks requiring monitoring, its efficacy makes it a significant therapeutic advance.